BIODYNE Co., Ltd. Overview
Biodyne is a Seoul-based in-vitro diagnostics company specialising in liquid-based cytology (LBC). LBC is the slide-preparation step used mainly in cervical cancer screening and in non-gynaecological cytology. Its core intellectual property is a patented "blowing" method, registered in 2013. In this method, air is blown over a filter so that cells are deposited evenly onto a slide, with less cell damage and overlap than sedimentation- or filter-based competitors. Biodyne sells its own PATHPLORER LBC instruments and reagent kits in Korea and through overseas distributors. Since 2019 its strategic centre of gravity has been an exclusive global licence with Roche Diagnostics. Roche embedded the blowing technology in the VENTANA SP400 slide-preparation instrument, launched in Japan in June 2025. Biodyne earns milestones and per-unit and per-vial royalties from this arrangement. Its revenue base is still small (KRW 7.0bn in FY2025), but its long-term earnings power is tied to how fast Roche rolls the SP400 out globally.
What the company does. Biodyne develops, manufactures and sells LBC slide-preparation equipment and the consumables used with it: sample-preservation vials and solutions, filters, and cancer-diagnostic reagent kits. LBC sits within anatomic or cellular pathology in the in-vitro diagnostics value chain. Cells shed naturally from tissue are collected into a liquid medium and then transferred as a thin, even layer onto a glass slide. A cytologist then examines the slide for malignant or pre-malignant change. The method applies to cervical (gynaecological) samples and to non-gynaecological specimens such as body fluids, urine and bronchial samples (Daishin IPO report, June 2021).
Company's own description. In its IPO materials and press briefings, management presented early cancer diagnosis as the best cancer treatment. It positioned the blowing technology as superior to existing LBC methods and stated an intention to expand into molecular and immunodiagnostics over time. At the IPO (January 2021), Biodyne said it exported its LBC equipment and consumables to 25 countries. Domestically, it supplied the five major Korean health-screening centres, universities and hospitals (BioSpectator, Jan 2021; iNews24, Mar 2021). An English-language annual report is not published.
Business model and revenue mix. Biodyne currently has two economic engines.
-
Own-brand product sales (instruments plus consumables). The PATHPLORER LBC systems are placed with laboratories, which then buy reagent kits and vials on an ongoing basis (a razor/razor-blade model). In Q2 2026, LBC diagnostic reagent kits were 78% of revenue and LBC equipment 22% (Butler, from the H1 2026 report).
-
Technology licensing to Roche. Roche holds exclusive global rights to the blowing technology under a 20-year contract that renews automatically every five years (Mirae Asset, Sept 2024). Biodyne's income from Roche has three parts:
-
Development and commercial milestones, totalling USD 6.75M over the life of the deal. The final USD 250,000 milestone was received in December 2025.
-
About KRW 3M per SP400 instrument sold during the first two years after launch.
-
A fixed royalty per LBC vial or test consumed on Roche systems. Sources: Finance Scope (Jun 2025); Edaily (Dec 2025).
-
Revenue is therefore a mix of product sales and licensing income. Biodyne does not separately disclose milestone or royalty revenue in the sources reviewed. A subscription model was not identified.
Value-chain position. Biodyne is an upstream technology originator and niche OEM. In its own sales channel it sells instruments and consumables directly or through distributors to laboratories. In the Roche channel it is a licensor and potential component or consumable supplier, while Roche owns the customer relationship, regulatory files and distribution. This makes Biodyne's long-term revenue increasingly dependent on its partner's commercial execution.
Customer types and end-markets.
-
Health-screening centres and hospital pathology labs in Korea.
-
Overseas distributors (25 countries at IPO).
-
Roche Diagnostics, as licensee and distribution partner, particularly Roche Japan, the first SP400 market.
The end-market is cervical cancer screening, with secondary non-gynaecological cytology applications.
Independent characterisation. Biodyne is best understood as a single-technology licensing story inside a small device business. The domestic product business provides KRW 5–7bn of annual revenue and has not been consistently profitable. The investment case rests almost entirely on Roche's ability to scale the SP400 and its consumable pull-through, and on whether cytology keeps its role in screening algorithms as primary HPV testing spreads.
Strategy
Stated strategic themes (paraphrased from IPO materials and management commentary; no English annual report or investor day exists):
-
Early diagnosis as the core mission. Win share in prevention and diagnostics with blowing-technology LBC.
-
Global big-pharma partnership as the commercial channel. Use credibility from the Roche partnership to reach global scale and widen collaboration with large IVD companies.
-
Manufacturing scale-up. Use IPO proceeds to build mass-production capacity and fund new businesses (BioSpectator, Jan 2021). Executed in 2025–2026 through Vietnam.
-
Portfolio extension. Move from cytology toward molecular and immunodiagnostics (BioSpectator, Jan 2021), and toward self-collection sampling (EarlyPop Brush; Edaily, Dec 2025).
Sustainability and ESG commitments. None publicly disclosed in sources reviewed.
Cost programmes. No formal programme was announced. Headcount fell from 36 to 19 between 2021 and 2023, with payroll-to-revenue falling from 20.8% to 12.8% by 2025 (ETF Shopping).
Medium-term financial targets and guidance. Biodyne does not publish formal financial guidance. Management indicated in December 2025 that PATHPLORER and reagent sales could grow 20–30% in 2025 (Edaily).
Products & Services
Biodyne has one product family plus a licensed technology, so the catalog is organised by product line. Detailed technical specifications, launch years and list prices for Biodyne's own products were not disclosed in the sources reviewed. Fields are marked ND where applicable.
Own-brand LBC instruments
| Product | Description | Key capabilities | Target customer | Launch / latest version | Pricing model | Source |
|---|---|---|---|---|---|---|
| PATHPLORER LBC System | Biodyne's base LBC slide-preparation solution using the patented blowing technology | Air is blown across a filter so cells deposit in an even monolayer. Positioned as reducing cell damage and overlap versus sedimentation (gravity/centrifuge) and filter-transfer methods. | Pathology labs, screening centres | — | Instrument sale plus consumables | Albamon (company history); Mirae Asset |
| PATHPLORER PLUS LBC System | Semi-automated version | Semi-automated slide preparation | Mid-volume labs | — | Instrument sale plus consumables | Albamon |
| PATHPLORER AUTO LBC System | Fully automated version, developed with Gyeonggi Province project support | Automated LBC processing. The company claims Korea's first fully automated cancer-screening equipment patent. | High-volume labs, screening centres | — | Instrument sale plus consumables | Albamon; Daum/Hankyung (Oct 2024) |
| Cellprep (PATHPLORER) | Earlier export brand of the LBC equipment; CE-marked together with diagnostic reagent kits | European IVD conformity | Export distributors (Europe and others) | CE date ND | Instrument sale plus consumables | Albamon |
Own-brand consumables and reagents
| Product | Description | Target customer | Notes | Source |
|---|---|---|---|---|
| LBC diagnostic reagent kits | Sample-preservation solution, vials, filters and processing reagents used on PATHPLORER systems | Installed-base labs | 78% of Q2 2026 revenue | Butler |
| Cancer-diagnosis reagents | Reagents for cytology-based cancer diagnosis (cervical and non-gynaecological) | Labs | Product-level breakdown ND | Morningstar profile |
Pipeline / new products
| Product | Description | Status | Source |
|---|---|---|---|
| EarlyPop Brush | Self-collection cervical sampling device. The company says it faces no major direct competitor. | 520-patient Korean study completed; CE-related publication under way (Dec 2025) | Edaily (Dec 2025) |
| Exfoliated-cell collection device (KR102009522B1) | Patented device for collecting exfoliated cells for uterine screening; likely the IP underlying EarlyPop | Granted 9 Aug 2019 | Google Patents |
| Molecular and immunodiagnostics | Stated ambition at IPO to move into molecular and immunodiagnostic segments | No commercial product identified | BioSpectator (Jan 2021) |
Licensed technology: Roche channel
| Product | Owner / seller | Description | Key specifications | Launch | Biodyne economics | Source |
|---|---|---|---|---|---|---|
| VENTANA SP400 | Roche Diagnostics | Benchtop, semi-automated LBC slide-preparation instrument embedding Biodyne's blowing technology. Described as Roche's first LBC slide-preparation device. | About 45 seconds per specimen; compact benchtop footprint; thin even smear that addresses drying-related cell degradation of direct smears | Japan, 23 Jun 2025; rollout to more than 40 countries planned for 2026 | About KRW 3M royalty per unit for the first two years; fixed royalty per vial or test; milestones totalling USD 6.75M (final USD 0.25M received Dec 2025) | Finance Scope (Jun 2025); Edaily (Dec 2025) |
| CINtec PLUS dual-stain (context only) | Roche | p16/Ki-67 dual-stain cytology triage test. Not a Biodyne product, but it creates demand for high-quality cytology slides. | Described as the only dual-stain test with FDA and CE clearance for triaging HPV-positive women | Existing | Indirect demand driver | Mirae Asset via Asia Business Daily (Sep 2024) |
Financial Narrative
Basis. FY2021–FY2024 are separate (non-consolidated) statements. FY2025 is consolidated (KRW bn unless stated). Source: DART business reports via ETF Shopping and Butler, except where noted. EPS figures are as reported by the aggregator. FY2021–FY2022 EPS appears to be on the pre-bonus-issue share count; adjusted figures from Kiwoom are shown separately.
Income statement
Notes:
-
FY2024 net income was KRW 10.77M, effectively breakeven (Digital Today).
-
Diluted EPS is not separately disclosed in sources reviewed.
-
The two EBITDA series differ between sources and both are shown.
Revenue CAGR FY2021–FY2025: about 16.5%: (KRW 3.8bn to KRW 7.0bn, 4 years). The path is highly non-linear because of the FY2022 spike.
Quarterly revenue and earnings (recent eight quarters plus FY2024)
Source: DART quarterly, half-year and annual reports via ETF Shopping.
H1 2026: revenue KRW 1.5bn, operating loss KRW 1.1bn, net loss KRW 0.1bn.
H1 2025: revenue KRW 2.7bn, operating loss KRW 0.5bn.
- Q2 2026 revenue fell 67.2% YoY.
Balance sheet
Sources and notes:
-
FY2024: Digital Today; Simply Wall St. Simply Wall St's cash figure may be for an interim date near FY2024.
-
FY2025: Kormedi (consolidated). Equity of KRW 44.07bn is implied by the Aug 2026 loan disclosure, where USD 2M (KRW 2.867bn) equals 6.5% of equity. The Kormedi article states equity as "4406억" (KRW 440.7bn); this is a scaling error and should read about KRW 44.1bn.
-
Kiwoom gives BPS of KRW 1,458 for FY2023 (bonus-adjusted), implying equity of about KRW 43bn.
Cash flow
Source: ETF Shopping (FY2025 FCF).
FY2025 FCF was negative despite positive net income. This is consistent with the KRW 4.3bn equity investment in Vietnam (classified as investing outflow at parent level and capex at consolidated level) and working-capital build ahead of SP400 supply.
Ratios
Notes:
-
FY2025 ROE: ETF Shopping reports 1.9%; Butler reports 2.8%. The difference is likely a denominator or TTM basis. Both are flagged.
-
Current ratio for FY2024 is calculated from Simply Wall St (KRW 22.4bn / 1.1bn).
-
Asset turnover is calculated as revenue divided by total assets.
-
Net debt/EBITDA and interest coverage are not meaningful because there is no debt.
Commentary on trends, inflections and drivers
Revenue. The five-year revenue line is dominated by one outlier. FY2022 revenue of KRW 12.2bn, up 224.5%, came with a 76.2% gross margin and a 54.7% operating margin, figures inconsistent with the company's product economics in other years. This is most plausibly explained by recognition of Roche technology-transfer or milestone income in the year the final 20-year contract was signed. The total disclosed milestone package of USD 6.75M is roughly KRW 8–9bn at prevailing rates. Excluding FY2022, underlying revenue grew from KRW 3.8bn (FY2021) to KRW 7.0bn (FY2025). Management attributed 2025 growth to rising cervical-screening demand and expected PATHPLORER and reagent sales to grow 20–30% in the year (Edaily, Dec 2025).
Gross margin. Gross margin improved from 16.7% (FY2023) to 46.2% (FY2024) and 63.6% (FY2025), while cost of sales fell from KRW 3.4bn to KRW 2.6bn on rising revenue. Two explanations fit this pattern: a shift toward higher-margin consumables and licence income, and better fixed-cost absorption. The Q4 2025 quarter (KRW 3.5bn revenue, KRW 1.5bn operating profit) coincides with receipt of the final USD 250k Roche milestone and the start of SP400 commercial supply. It accounts for half of FY2025 revenue and all of its operating profit. Without Q4 2025, FY2025 would have been loss-making at the operating line.
2026 reversal. H1 2026 revenue of KRW 1.5bn was down about 44% on H1 2025, and the operating loss widened to KRW 1.1bn. Q2 2026 revenue of KRW 0.6bn was the lowest quarterly figure in the ten quarters reviewed. The sources reviewed contain no management explanation. Plausible drivers, none confirmed, include:
-
Lumpy Roche stocking orders after the Q4 2025 initial supply.
-
Japan-only SP400 sales before the multi-country rollout.
-
A royalty-reporting lag, since Japan royalties were expected to start in Q1 2026 (Edaily).
-
Weaker own-brand domestic sales.
This is the most important open question for the equity.
Profitability. Biodyne recorded operating losses in four of the five years before FY2025, with operating margins between -32.8% and -62.2% in loss years. Its cost base is small: payroll was about KRW 0.9bn in FY2025, 12.8% of separate revenue (ETF Shopping). Incremental high-margin royalty income would therefore flow through to operating profit at a very high rate.
Balance sheet. The balance sheet is conservative. Equity is about KRW 44bn with no financial debt and liabilities near KRW 1bn. Most of the equity comes from the March 2021 IPO, which raised about KRW 30.9bn gross at the KRW 30,000 offer price. Liquidity is ample relative to the cash burn rate of roughly KRW 2–3bn a year. However, the Vietnam programme (KRW 4.3bn equity plus USD 4M, about KRW 5.7bn, of intercompany loans) is a significant claim on cash relative to revenue.
Cash returns. Biodyne has paid no dividends and has no evident buyback programme. Treasury stock is about 0.97%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Category Details
| Product category (Q2 2026 revenue basis) | Share of revenue (%) | Source |
|---|---|---|
LBC diagnostic reagent kits (consumables) | 78 | Butler (H1 2026 report) |
LBC equipment (instruments) | 22 | Butler (H1 2026 report) |
Revenue by Segment and Segment Margins & Growth (%)
| Segment (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total company / single segment revenue | 4.1 | 5.3 | 7.0 |
Total company / single segment operating income | -2.1 | -1.7 | 0.7 |
Operating margin (%) | -50.2 | -32.8 | 9.3 |
Revenue growth YoY (%) | -66.5 | 28.9 | 33.3 |
Group Entities
| Entity | Country | Ownership | Function | FY2025 total assets (KRW Bn) | FY2025 net income (KRW Mn) | Source |
|---|---|---|---|---|---|---|
BIODYNE CO., LTD. (parent) | Korea | Listed | R&D, manufacturing, sales, licensing | 44.9 (consolidated) | 900 (consolidated) | Kormedi; ETF Shopping |
BIODYNE VIETNAM CO., LTD | Vietnam | 100% | Manufacturing of medical devices and medical supplies | 4.43 | -6.55 | ETF Shopping; Digital Today |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 3.8 | 12.2 | 4.1 | 5.3 | 7.0 |
Cost of sales (KRW Bn) | 3.3 | 2.9 | 3.4 | 2.8 | 2.6 |
Gross profit (KRW Bn) | 0.5 | 9.3 | 0.7 | 2.4 | 4.5 |
Operating income (KRW Bn) | -2.3 | 6.7 | -2.1 | -1.7 | 0.7 |
EBITDA (KRW Bn, ETF Shopping) | -1.8 | 7.4 | — | — | — |
EBITDA (KRW Bn, Kiwoom) | -1.0 | 8.2 | -0.4 | — | — |
Pre-tax income (KRW Bn, Kiwoom) | -11.1 | 7.4 | -1.2 | — | — |
Net income (KRW Bn) | -10.9 | 5.6 | -1.0 | 0.0 | 0.9 |
EPS basic as reported (KRW) | -1,836 | 910 | -33 | 0 | 29 |
EPS adjusted for 2024 bonus issue (KRW, Kiwoom) | -378 | 189 | -33 | — | — |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Gross margin (%) | 13.2 | 76.2 | 16.7 | 46.2 | 63.6 |
Operating margin (%) | -62.2 | 54.7 | -50.2 | -32.8 | 9.3 |
EBITDA margin (%) | -47.1 | 60.7 | — | — | — |
Net margin (%) | -288.5 | 46.0 | -24.3 | 0.2 | 12.1 |
Revenue growth YoY (%) | 2.5 | 224.5 | -66.5 | 28.9 | 33.3 |
Income Statement
| Metric (KRW Bn) | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.1 | 1.2 | 1.5 | 1.4 | 0.9 | 1.8 | 0.9 | 3.5 | 0.9 | 0.6 |
Operating income | -0.5 | -0.3 | -0.4 | -0.6 | -0.8 | 0.3 | -0.4 | 1.5 | -0.4 | -0.7 |
Net income | -0.2 | 0.2 | -0.4 | 0.4 | -0.4 | -0.1 | 0.0 | 1.4 | 0.2 | -0.3 |
Balance Sheet
| Metric (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Total assets | 44.3 | 44.9 |
Total liabilities | 1.1 | 0.9 |
Total equity | 43.2 | 44.1 |
Cash and equivalents (incl. short-term financial assets where reported) | 20.7 | — |
Total debt | 0.0 | — |
Short-term debt | 0.0 | — |
Long-term debt | 0.0 | — |
Net debt (negative = net cash) | -20.7 | — |
Current assets | 22.4 | — |
Current liabilities | 1.1 | — |
Working capital | 21.3 | — |
Cash Flow
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Free cash flow | — | — | — | — | -2.6 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | — | — | — | 0.0 | 1.9 |
ROA (%) | — | — | — | 0.0 | 1.9 |
Current ratio (x) | — | — | — | 20.4 | — |
Debt/equity (%) | — | — | — | 0.0 | — |
Asset turnover (x) | — | — | — | 0.12 | 0.16 |
P/B at period-end price (x, Kiwoom) | 5.35 | 3.19 | 9.27 | — | — |
Revenue by Region
| Region (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total | 4.1 | 5.3 | 7.0 |
Share Price & Returns
| Date | Event | Unadjusted price | Bonus-adjusted price | Source |
|---|---|---|---|---|
17 Mar 2021 | IPO offer price | 30,000 | 6,000 | Economist.co.kr |
28 Jun 2021 | Daishin initiation | 42,500 | 8,500 | Daishin |
7 Jun 2024 | Kiwoom report | 12,220 (post-bonus) | 12,220 | Kiwoom |
25 Sep 2024 | Post-listing intraday high | 18,460 | 18,460 | Asia Business Daily |
Mid-Dec 2025 | Roche milestone news | 16,310 | 16,310 | Edaily |
3 Aug 2026 | Vietnam loan disclosure | 8,110 | 8,110 | Kormedi |
8 Oct 2026 | Latest verified close | 6,520 | 6,520 | ETF Shopping |
Share Price & Returns by Horizon
| Horizon | Return | Basis | Source |
|---|---|---|---|
1 month (to 8 Oct 2026) | -8.8% | Price | ETF Shopping |
6 months | -44.6% | Price | ETF Shopping |
1 year | -58.6% | Price | ETF Shopping |
Since IPO (about 5.5 years) | About +8.7% | KRW 6,000 adjusted IPO price to KRW 6,520; calculated | Calculated |
Valuation Multiples
| Multiple | Biodyne | Basis | Peer comparison |
|---|---|---|---|
P/E (trailing) | About 224.8x | FY2025 EPS of KRW 29 | Not meaningful vs profitable IVD peers; peer multiples not researched |
EV/Sales | About 24.8x | (KRW 194.1bn − about KRW 20.7bn cash) / KRW 7.0bn; the cash figure may be dated | Peer multiples not researched |
P/S | About 27.7x | KRW 194.1bn / KRW 7.0bn | — |
P/B | 4.41x | ETF Shopping / Butler | — |
Capital Markets
| Item | Status | Source |
|---|---|---|
Dividend history | None paid since listing | Simply Wall St; ETF Shopping |
Dividend policy | No stated policy found | — |
Buyback authorisation | None identified; treasury shares about 0.97% | Butler |
Bonus issues | 4-for-1 (decided 14 Feb 2024) | ETF Shopping |
Credit ratings (Moody's / S&P / Fitch) | Not rated | — |
Debt maturity profile | No financial debt outstanding | Simply Wall St |
Valuation Multiples (x) and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Shares outstanding (M, year-end) | — | — | 6.18 | 29.76 | 29.76 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
P/B at year-end (x, Kiwoom) | 5.35 | 3.19 | 9.27 | — | — |
Insider plus related-party ownership (%) | 49.22 | 49.37 | 49.38 | 47.16 | 41.85 |
Analyst Conclusions
Management guidance and projections
| Source | Date | Projection | Status |
|---|---|---|---|
| Kiwoom Securities | Jun 2024 | FY2024 revenue KRW 20.0bn, operating profit KRW 10.6bn, net income KRW 8.7bn | Missed: actual KRW 5.3bn / -KRW 1.7bn / KRW 0.01bn |
| Eugene Investment | 2,024 | 2029 revenue KRW 91.4bn; 2029 operating profit KRW 62.6bn; Roche LBC share above 40% by 2029 | Long-dated |
| Asia Business Daily headline, attributing a conservative scenario | Sep 2024 | 2029 operating profit KRW 150bn | Conflicts with Eugene's KRW 62.6bn; source of the figure unclear |
| Unnamed analysts cited by Edaily | Dec 2025 | Annual SP400 royalty and consumable revenue above KRW 40bn from 2028 | Long-dated |
Company guidance: No formal numerical guidance. In December 2025, management expected 20–30% growth in PATHPLORER and related reagent sales for 2025 and said royalties from Japanese SP400 sales would start in Q1 2026 (Edaily).
Partner plans: Roche intended to roll the SP400 out to more than 40 countries in 2026 (Edaily).
Bull case
-
Royalty ramp with near-100% incremental margin. More than 400 SP400 units were placed in about seven months (Jan 2026), with a 40+-country rollout planned. Fixed per-vial royalties on a growing installed base could take revenue well above the current KRW 5–7bn base on a cost structure of about KRW 0.9bn payroll.
-
Guideline tailwinds for Roche's integrated cervical workflow. Roche combines HPV testing (cobas), dual-stain triage (CINtec PLUS, cited in the 2024 WHO guideline revision) and now LBC slide preparation (SP400). This gives Roche an incentive to push SP400 placements to protect and pull through its higher-value tests.
-
Balance-sheet optionality. About KRW 44bn equity and no debt fund the Vietnam ramp and EarlyPop commercialisation without dilution. At about KRW 6,500 the stock trades close to the adjusted IPO price of KRW 6,000, so the market is largely discounting the Roche optionality that drove the shares to KRW 16,000–18,000.
Bear case
-
Revenue has not followed the launch. H1 2026 revenue of KRW 1.5bn was down about 44% YoY, and Q2 2026 of KRW 0.6bn was a ten-quarter low, even though Japan royalties were due to start in Q1 2026. If royalty volumes are small or reported with long lags, the earnings inflection may be years away.
-
Structural headwind from HPV-first screening. Primary HPV testing and self-sampling reduce routine cytology volume, and incumbents (Hologic, BD/Waters) hold the installed base, so SP400 share gains may be slower than the 40%-by-2029 thesis assumes.
-
Governance and forecast credibility. The CEO sold about KRW 17.9bn of stock near the highs in August 2025. Executive pay exceeds operating profit. Prior sell-side forecasts (Kiwoom FY2024) were missed by a wide margin, so long-dated projections deserve heavy discounting.
Key catalysts and monitorables (next 12 months)
-
Q3 2026 report (about 14–18 Nov 2026). The key test is whether revenue recovers from KRW 0.6bn and whether royalty income becomes visible.
-
FY2026 business report (about March 2027). Watch for any disclosure of royalty or licence revenue by nature, and for SP400 country launches.
-
Roche disclosures on SP400 country rollouts, especially Europe and any US regulatory path, and placement counts.
-
Vietnam subsidiary. Start of production, quality certification and any further capital calls beyond the USD 4M of loans.
-
EarlyPop Brush. CE-mark or publication milestones and first commercial orders.
-
Large-holding and insider filings, following the July–August 2026 reports, for further changes in the controlling shareholder's position.
-
Market regime. KOSDAQ liquidity after the 15 October 2026 KOSPI circuit-breaker event.
Analyst verdict
Biodyne is a technology-licensing option attached to a sub-scale cytology device business, and it should be valued that way. The core asset is real. Roche ran a multi-year validation before signing a 20-year exclusive contract, paid the full USD 6.75M milestone schedule by December 2025, and placed more than 400 VENTANA SP400 instruments within months of the Japan launch. Few small-cap Korean diagnostics firms can show that degree of external validation from the world's largest IVD company. The balance sheet is clean, with about KRW 44bn of equity and no debt, so the downside from financial distress is limited.
The reported numbers, however, do not yet support the investment narrative. FY2025's first operating profit since 2022 came entirely from one quarter that coincided with the final milestone. H1 2026 revenue then fell about 44% and losses resumed, despite guidance that Japanese royalties would begin in Q1 2026. Biodyne does not disclose royalty volumes, revenue by nature or geographic mix, so investors cannot distinguish a timing lag from weak sell-through. Prior forecasts missed badly. The structural shift to HPV-first screening and the installed-base advantage of Hologic and BD/Waters argue for a slower ramp than the 2024 sell-side models assumed.
The 2026 share-price decline has largely reset expectations: the stock now trades close to its bonus-adjusted IPO price. That makes the risk/reward more balanced than at the 2024–2025 peaks, but it is still not cheap on any earnings metric (about 225x trailing P/E, about 25x EV/Sales). The equity case turns on one observable variable: royalty-bearing revenue visibly compounding in the quarterly reports from Q3 2026 onward. Until that appears, Biodyne remains a high-volatility, event-driven position.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Compensation (FY2025) | Shareholding | Source |
|---|---|---|---|---|---|
Lim Wook-bin (임욱빈) | CEO and representative director; largest shareholder | CEO throughout listed period (since at least 2020); founder-level tenure likely | KRW 1.0bn total (individual disclosure applies above KRW 0.5bn) | 40.39% (12,022,729 shares after Aug 2025 sale) | ETF Shopping; Digital Today |
Yang Geun-ho (양근호) | Registered officer (title ND) | — | Within board average | 0.05% | ETF Shopping |
Ko Yu-ra (고유라) | Registered officer (title ND) | — | Within board average | 0.01% | ETF Shopping |
Outside director(s) | Independent director | — | — | — | Kormedi (one outside director attended the 3 Aug 2026 board) |
Statutory auditor | Auditor (감사) | — | — | — | Kormedi (auditor attended the 3 Aug 2026 board) |
Board & Management Changes
| Date | Event | Source |
|---|---|---|
8 Aug 2025 | CEO sold 1,157,510 shares after hours at KRW 15,500 (about KRW 17.9bn); stake fell from 44.28% to 40.39% | Digital Today |
Dec 2025 | Senior executives bought shares on market, describing the stock as undervalued (names and amounts ND) | Edaily |
Major Shareholders
| Holder | Relationship | Stake (%) | As of | Source |
|---|---|---|---|---|
Lim Wook-bin | Largest shareholder (CEO) | 40.39 | FY2025 year-end | ETF Shopping |
Hong Jeong-wan | CEO's brother-in-law | 1.18 | FY2025 year-end | ETF Shopping |
Lim Jeong-bin | CEO's sister | 0.22 | FY2025 year-end | ETF Shopping |
Yang Geun-ho | Registered officer | 0.05 | FY2025 year-end | ETF Shopping |
Ko Yu-ra | Registered officer | 0.01 | FY2025 year-end | ETF Shopping |
Largest shareholder plus related parties | — | 41.85 | FY2025 year-end | ETF Shopping |
National Pension Service | Institutional | 0.37 | FY2024 year-end | ETF Shopping |
Treasury shares | Company | 0.97 | 2,026 | Butler |
Foreign investors | Aggregate | 1.9 | Jun 2024 | Kiwoom |
ETF holders (TIGER Medical Devices, KODEX Healthcare, KODEX Growth) | Passive | Small (ETF weights 0.0–0.8%) | 2,026 | ETF Shopping |
Governance Overview
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Largest shareholder + related parties (%) | 49.22 | 49.37 | 49.38 | 47.16 | 41.85 |
Competitive Landscape
Market Share by Competitor
| # | Competitor | Segment overlap | Flagship offering | Relevant revenue / share (where available) | Relative positioning vs Biodyne | Source |
|---|---|---|---|---|---|---|
| 1 | Hologic Inc. (US) | LBC slide prep and consumables; HPV | ThinPrep Pap Test; Genius Digital Diagnostics; Aptima HPV | Cervical-dx revenue about USD 550M, about 25.5% share (secondary estimate, 2024–25) | Global LBC incumbent with large installed base and US FDA-cleared workflow; Biodyne/Roche is a challenger | ReportPrime |
| 2 | Becton, Dickinson & Co. / Waters Corp. (US) | LBC (SurePath); HPV (Onclarity) | BD SurePath LBC; BD Onclarity HPV; FocalPoint | BD cervical-dx revenue about USD 180M, about 8.4% share (secondary estimate) | Second LBC incumbent. BD's Biosciences & Diagnostic Solutions unit was combined with Waters (deal completed Feb 2026), so ownership of the SurePath/Onclarity franchise should be verified. | ReportPrime; Yahoo Finance (Feb 2026) |
| 3 | Maccura Biotechnology (China) | Automated LBC systems | Liquid-based cytology systems | — | Low-cost Asian challenger in LBC instruments and consumables | Intel Market Research |
| 4 | Thermo Fisher Scientific (US) | Cytology fixatives and consumables | Cytology fixatives | — | Consumables competitor in preservation media | Future Market Insights |
| 5 | Roche Diagnostics (Switzerland) | HPV molecular (cobas), dual-stain (CINtec PLUS); partner, not competitor, in LBC | cobas HPV; CINtec PLUS; VENTANA SP400 | — | Strategic partner. Its HPV-first strategy can also reduce cytology volume per woman screened. | Mirae Asset |
| 6 | Abbott (US) | HPV molecular screening | Alinity m HR HPV | — | Competes for the primary-screening test that triggers cytology | Mirae Asset (named as a follower in cytology/screening) |
| 7 | Qiagen (Netherlands/Germany) | HPV molecular | HPV assays | — | Molecular-screening competitor | Mirae Asset (named as a follower) |
| 8 | Seegene (Korea) | HPV molecular (domestic) | Multiplex PCR HPV assays | — | — | — |
| 9 | Other Asian LBC entrants | LBC instruments and consumables | Various | — | Identified as a threat to incumbents in a secondary market report | ReportPrime |
| 10 | Conventional Pap smear (method substitute) | Slide prep | Manual direct smear | — | Low-cost incumbent method; LBC displaces it on quality | Finance Scope; Mirae Asset |
Peer Comparison FY2025
| Metric | Biodyne | Hologic | BD (Diagnostic Solutions / now Waters) |
|---|---|---|---|
Group revenue, latest FY | KRW 7.0bn (FY2025) | — | — |
Cervical-dx revenue (secondary estimate) | — | About USD 550M | About USD 180M |
Revenue growth, latest FY | +33.3% | — | — |
Operating margin, latest FY | 9.3% | — | — |
“—” = not publicly disclosed.



